With Thanksgiving behind us here's a few biotech/ healthcare companies that might be worth looking at before after your meal
HENDERSON, NV / ACCESSWIRE / November 26, 2018 / Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Auris Medical Holding AG (EARS), PDL BioPharma, Inc. (PDLI), Geron Corporation (GERN), and Cronos Group, Inc. (CRON).
With the holidays upon us and the enormous amount of food consumed especially Thursday, it's an opportune time to look at America's obesity problem. Obesity costs the US $1.72 Trillion annually between healthcare costs and decreased productivity. Companies with winning remedies to this problem will see their market cap grow like their potential patients' waists.
One interesting company tackling this issue is, BioRestorative Therapies, Inc. (BRTX) (Market Cap: $10.4M Share Price: $0.99) a life sciences company focused on stem cell-based therapies, developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
Another healthcare stock under a dollar dealing with weight gain, Auris Medical Holding AG (EARS) (Market Cap: $20.27M Share Price: $0.68). While BRTX's therapy focuses on obestity EARS is focused on anti-psychotic med induced weight gain. The FDA recently commented on their multiple dose Phase 1 trial with AM-201 administered to healthy subjects in combination with olanzapine to evaluate the pharmacokinetics, pharmacodynamics, and safety, and to establish proof-of-concept. Further, the FDA endorsed weight gain normalized to baseline body weight versus placebo as reasonable primary efficacy endpoint for a subsequent Phase 2 trial. This is worth monitoring.
Investors monitoring PDL BioPharma, Inc. (PDLI) (Market Cap: $423.33M Share Price: $2.90) were pleased when the company reported its financial results for the three and nine months ended September 30, 2018 this week. Highlights included total revenues of nearly $68 million as well as the completion of a $25 million share repurchase program.
Another healthcare stock recently reporting, Geron Corporation (GERN). (Market Cap: $283.24M Share Price: $1.52) has pulled back since seeing a nice bit of momentum tied to the numbers. GERN recently reported a loss of 3 cents per share for the third quarter of 2018, narrower than the Zacks Consensus Estimates of a loss of 5 cents and the year-ago quarter loss of 4 cents. Quarterly revenues increased 1.2% from the year-ago quarter to $0.17 million, which missed the Zacks Consensus Estimate of $0.22 million. Revenues comprised royalty and license fee revenues received under various non-imetelstat license agreements.
A biotech/ cannabis hybrid seeing a lot of action recently caps off the companies we are watching in the biotech/ healthcare industry, Cronos Group, Inc. (CRON) (Market Cap: $1.47B Share Price: $8.20).
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to received a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC